2BB score and signals
Neuphoria Therapeutics Inc.’s current 2BB score is 21 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 33 | Weak |
| Quality | 20 | Weak |
| Risk | 42 | Moderate |
Company facts
| Headquarters | Burlington, Massachusetts, United States |
| Founded | 1996 |
| Employees | 8 |
| 52-week range | $3.19 – $21.40 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-15 | — | -1.5045 | — | $0.00 |
| 2026-11-12 | — | -1.4739 | — | $0.00 |
| 2026-09-28 | — | -0.5712 | — | $0.00 |
| 2026-05-15 | -0.09 | -0.9894 | $0.00 | $0.00 |
Related companies
